This trial aims to evaluate the safety and effectiveness of the patient's own bone marrow stem cell in chronic spinal cord injury. The trial is being conducted by the Asian Medical Centre in Seoul in conjunction with biotech Pharmicell Co Ltd. The trial expects to enrol 32 patients with chronic spinal cord injury between August 2008 and September 2014. This trial follows on from a phase 1 trial that established the safety of the procedure. Participants will be injected with their own cells that have been obtained from bone marrow and expanded in the laboratory. The cells will be injected into the fluid surrounding the spinal cord following spinal surgery (posterior cervical laminectomy). Participants will be monitored for complications and changes in motor and sensory function.